APOC3 and PNPLA3 in non-alcoholic fatty liver disease: Need to clear the air

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 5, 2012, Pages 848-851

  Duseja, Ajay ^a   Aggarwal, Rakesh ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN D; APOLIPOPROTEIN E; BETA2 GLYCOPROTEIN 1; NEUROCAN; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 3; PEPTIDES AND PROTEINS; PHOSPHOPROTEIN PHOSPHATASE 1; UNCLASSIFIED DRUG;

BODY MASS; CHROMOSOME 11; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; EDITORIAL; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

EID: 84860246738     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07103.x     Document Type: Editorial

References (21)

1. Browning JD, Szczepaniak LS, Dobbins R etal. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
2. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 163-72.
3. Duseja A, Sharma B, Kumar A etal. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology 2010; 52: 2248-9.
4. Miller M, Rhyne J, Chen H etal. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch. Med. Res. 2007; 38: 444-51.
5. Petersen KF, Dufour S, Hariri A etal. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 2010; 362: 1082-9.
6. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011; 53: 467-74.
7. Valenti L, Nobili V, Al-Serri A etal. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J. Hepatol. 2011; 55: 1409-14.
8. Sentinelli F, Romeo S, Maglio C etal. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis. 2011; 10: 93.
9. Peter A, Kantartzis K, Machicao F etal. Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. Int. J. Obes. (Lond) 2011; [Epub ahead of print] doi: 10.1038/ijo.2011.154.
10. Hyysalo J, Stojkovic I, Kotronen A etal. Genetic variation in PNPLA3 but not APOC3 influences liver fat in NAFLD. J. Gastroenterol. Hepatol. 2012; 27: 951-6.
11. van Hoek M, van Herpt TW, Dehghan A etal. Association of an APOC3 promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons. Diabetologia 2011; 54: 1360-7.
12. Ruiz-Narváez EA, Sacks FM, Campos H. Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction. Am. J. Clin. Nutr. 2008; 87: 1932-8.
13. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J. Clin. Invest. 1995; 96: 2601-5.
14. Romeo S, Kozlitina J, Xing C etal. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008; 40: 1461-5.
15. Valenti L, Al-Serri A, Daly AK etal. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-17.
16. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-94.
17. Valenti L, Alisi A, Galmozzi E etal. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52: 1274-80.
18. Cox AJ, Wing MR, Carr JJ etal. Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus. Diabetes Metab. 2011; 37: 452-5.
19. Speliotes EK, Yerges-Armstrong LM, Wu J etal. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011; 7: e1001324.
20. Trépo E, Pradat P, Potthoff A etal. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011; 54: 60-9.
21. Nischalke HD, Berger C, Luda C etal. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS ONE 2011; 6: e27087.